MIRA Pharmaceuticals Announces Ketamir-2’s Oral Bioavailability Predicted To Be 80%
New Data from IQVIA Supports Potential $3 Billion Annual MarketBALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical